MNV
Market News Video
MNV MNV The 10 Most Popular Large-Caps in ETFs
MNV
MNV
MNV
MNV
MNV
MNV
MNV
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

Analysts Expect 38% Gains Ahead For The Holdings of IBBQ
Wednesday, July 12, 7:39 AM ET, by Market News Video Staff

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...

Commit To Buy Atara Biotherapeutics At $0.50, Earn 24.2% Annualized Using Options
Monday, January 22, 2:33 PM ET, by Market News Video Staff

Investors eyeing a purchase of Atara Biotherapeutics Inc (ATRA) stock, but cautious about paying the ...

Commit To Purchase Atara Biotherapeutics At $0.50, Earn 22.3% Annualized Using Options
Tuesday, April 9, 11:29 AM ET, by Market News Video Staff

Investors eyeing a purchase of Atara Biotherapeutics Inc (ATRA) shares, but tentative about paying the ...

Commit To Buy Atara Biotherapeutics At $0.50, Earn 24.2% Annualized Using Options
Monday, April 22, 12:51 PM ET, by Market News Video Staff

Investors eyeing a purchase of Atara Biotherapeutics Inc (ATRA) shares, but cautious about paying the ...

Bag This Bargain Even Cheaper Than Chief Commercial Officer Yarema Did

By Market News Video Staff, Wednesday, July 7, 10:04 AM ET
Play Video: One Reason For Insiders to Buy


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Email EnvelopeFree Email Alerts By Stock:
Get Dividend Alerts
Get SEC Filing Alerts

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on June 14, Atara Biotherapeutics Inc's Chief Commercial Officer, Kristin Yarema, invested $500,369.64 into 34,354 shares of ATRA, for a cost per share of $14.57. Bargain hunters tend to pay particular attention to insider buys like this one, because presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money.

In trading on Wednesday, bargain hunters could buy shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) and achieve a cost basis even cheaper than Yarema, with shares changing hands as low as $14.56 per share. Atara Biotherapeutics Inc shares are currently trading down about 8.5% on the day. The chart below shows the one year performance of ATRA shares, versus its 200 day moving average:

Atara Biotherapeutics Inc Chart

Looking at the chart above, ATRA's low point in its 52 week range is $11.33 per share, with $28.20 as the 52 week high point — that compares with a last trade of $14.48. By comparison, below is a table showing the prices at which ATRA insider buying was recorded over the last six months:

Purchased Insider Title Shares Price/Share Value
06/14/2021 Kristin Yarema Chief Commercial Officer 34,354 $14.57 $500,369.64

Special Offer: Join the income investing conversation on ValueForum.com with a special Seven Days for Seven Dollars invitation.


This Article's Word Cloud:   ATRA   Atara   Back   Bargain   Bargains   Biotherapeutics   Cheaper   Chief   Commercial   Days   Dollars   Insider   Insiders   Join   June   Kristin   Looking   Offer   Officer   Price   Purchased   Seven   Share   Shares   Special   Start   Street   Than   There   Title   Yarema   about   below   buying   chart   cost   hunters   insider   last   only   point   reason   share   shares   stock   that   their   trading   week   with
MNV
MNV
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy
MNV
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV
MNV MNV Portfolio Channel Stock Market Definitions
MNV

Bag This Bargain Even Cheaper Than Chief Commercial Officer Yarema Did | Market News Video | Copyright © 2008 - 2024, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.

X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.